W

ith longer follow-up out to one year, bleeding episodes have been almost completely eliminated for a small group of hemophilia B patients infused once with an experimental gene therapy from Spark Therapeutics (ONCE).

The updated results from Spark’s Phase 1/2 clinical trial, published Wednesday night in the New England Journal of Medicine, provide further evidence to support a groundbreaking change in the way the inherited blood-clotting disorder is treated — and potentially cured.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.